TORONTO - Quantum BioPharma Ltd. (NASDAQ:QNTM) announced today it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, beginning on June 8, 2026.
Under the six-month agreement, the agency will communicate information about the company, create company profiles, distribute media to the financial community, build a digital community, market news distribution, and conduct lead generation campaigns. The fee for these services is $250,000.
IR Agency LLC is arm’s-length to the company and neither the agency nor its principals hold equity interest in Quantum’s securities or the right to acquire any equity interest, according to the press release statement. Rafael Pereira of the agency will provide the investor relations services.
Quantum BioPharma is a biopharmaceutical company focused on developing therapies for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its subsidiary Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a compound designed to address myelin degradation in multiple sclerosis.The stock currently trades at $5.25 with a market cap of $33.92 million, though shares have experienced significant volatility recently, declining 25.5% over the past week. According to an InvestingPro tip, the stock generally trades with high price volatility. InvestingPro analysis suggests the stock may be undervalued at current levels, with 10 additional ProTips available to subscribers.
The company also invented UNBUZZDâ„¢ and spun out its over-the-counter version to Unbuzzd Wellness Inc. Quantum retains 19.84% ownership of Unbuzzd as of March 31, 2026, and receives royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity.
In other recent news, Quantum BioPharma Ltd. announced significant progress in its collaborative study with Massachusetts General Hospital. The study has reached the halfway point in patient enrollment, with promising preliminary imaging results. This research aims to validate a PET imaging technique that can directly assess demyelinated neurons with intact axons and track demyelination in multiple sclerosis patients. The PET tracer used in the study, [¹⁸F]3F4AP, was developed by Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School. These developments are part of Quantum BioPharma’s ongoing efforts to advance medical imaging techniques. The recent progress in this study may have implications for future treatment approaches for multiple sclerosis. While the company did not provide specific earnings or revenue updates, the advancements in their research could potentially impact their future financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for QNTM plus thousands of other stocks and find your next hidden gem with massive upside.